Spyre Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.95 | -$0.95 | -$0.95 |
| Q2 2024 | 3 | -$0.82 | -$0.82 | -$0.82 |
| Q3 2024 | 5 | -$1.22 | -$0.95 | -$1.05 |
| Q1 2025 | 1 | -$0.97 | -$0.97 | -$0.97 |
| Q2 2025 | 1 | -$1.05 | -$1.05 | -$1.05 |
| Q3 2025 | 1 | -$1.03 | -$1.03 | -$1.03 |
| Q4 2025 | 1 | -$1.04 | -$1.04 | -$1.04 |
| Q1 2026 | 1 | -$0.85 | -$0.85 | -$0.85 |
| Q2 2026 | 1 | -$0.81 | -$0.81 | -$0.81 |
| Q3 2026 | 1 | -$0.82 | -$0.82 | -$0.82 |
| Q4 2026 | 1 | -$0.82 | -$0.82 | -$0.82 |
| Q1 2027 | 1 | -$0.69 | -$0.69 | -$0.69 |
| Q2 2027 | 1 | -$0.70 | -$0.70 | -$0.70 |
| Q3 2027 | 1 | -$0.71 | -$0.71 | -$0.71 |
| Q4 2027 | 1 | -$0.72 | -$0.72 | -$0.72 |
Spyre Therapeutics, Inc. Earnings Date And Information
Spyre Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-1.36 earnings per share for the quarter, missing analysts' consensus estimates of $-0.8 by $0.56. The company had revenue of 0 for the quarter and had revenue of 886,000 for the year. Spyre Therapeutics, Inc. has generated $-49 earnings per share over the last year ($-49.12 diluted earnings per share) and currently has a price-to-earnings ratio of -6.79. Spyre Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based on prior year's report dates.
Spyre Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/18/2024 | Q3 2024 | -$1.36 | $0 | $0 | ||
| 08/07/2024 | Q2 2024 | -$0.90 | -$0.86 | 0.04 | $6.67 M | $0 |
| 05/09/2024 | Q1 2024 | -$0.90 | -$1.20 | -0.3 | $0 | |
| 02/29/2024 | Q4 2023 | -$0.48 | -$11.29 | -10.81 | $1.04 M | |
| 09/29/2023 | Q3 2023 | -$9.34 | $198,000 | $0 | ||
| 06/29/2023 | Q2 2023 | -$56.79 | $198,000 | $688,000 | ||
| 03/30/2023 | Q1 2023 | -$4.89 | $198,000 | |||
| 12/29/2022 | Q4 2022 | -$7.20 | $168,000 | |||
| 09/28/2022 | Q3 2022 | -$4.84 | $208,333 | $174,000 | ||
| 06/28/2022 | Q2 2022 | -$6.79 | $709,500 | $625,000 | ||
| 03/29/2022 | Q1 2022 | -$9.26 | $1.36 M | |||
| 12/29/2021 | Q4 2021 | -$10.36 | $3.64 M | |||
| 09/28/2021 | Q3 2021 | -$7.72 | $4.05 M | $1.40 M | ||
| 06/28/2021 | Q2 2021 | -$2.60 | $12.15 M | $13.70 M |
Spyre Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Spyre Therapeutics, Inc.'s earnings date?
Spyre Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates.
-
How can I listen to Spyre Therapeutics, Inc.'s earnings conference call?
The conference call for Spyre Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Spyre Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Spyre Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Spyre Therapeutics, Inc. generate each year?
Spyre Therapeutics, Inc. (:SYRE) has a recorded annual revenue of $886,000.
-
How much profit does Spyre Therapeutics, Inc. generate each year?
Spyre Therapeutics, Inc. (:SYRE) has a recorded net income of $886,000. Spyre Therapeutics, Inc. has generated $-49.12 earnings per share over the last four quarters.
-
What is Spyre Therapeutics, Inc.'s price-to-earnings ratio?
Spyre Therapeutics, Inc. (:SYRE) has a price-to-earnings ratio of -6.79 and price/earnings-to-growth ratio is -0.11.
